Pediatric Study Compliance Could Face Scrutiny In PDUFA Renewal
Executive Summary
FDA says compliance is on par with other postmarketing requirements, but jury is still out on whether public posting of noncompliance letters has been effective tool to ensure timely trial completion.
You may also be interested in...
PDUFA VI: Pediatrics Group Seeks Earlier And Faster Studies
American Academy of Pediatrics’ legislative proposals for user fee bill also include eliminating automatic orphan drug exemption from Pediatric Research Equity Act study requirements.
Opioid Studies In Children Still Facing Design Challenges
FDA cites Purdue and Mallinckrodt over required assessments for Dilaudid and Xartemis XR, respectively; Merck also draws letter for failing to timely submit a PREA study labeling change for the antibiotic Cubicin.
Opioid Studies In Children Still Facing Design Challenges
FDA cites Purdue and Mallinckrodt over required assessments for Dilaudid and Xartemis XR, respectively; Merck also draws letter for failing to timely submit a PREA study labeling change for the antibiotic Cubicin.